- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02915094
Kineret in the Treatment of Rheumatoid Arthritis
August 10, 2017 updated by: Swedish Orphan Biovitrum
Objective of the study is to gain knowledge about the administration of Kineret in patients with rheumatoid arthritis in the daily routine treatment and not in controlled trials.
In the current survey, the investigation of the response rate of Kineret regarding the date of onset of action, the efficacy, as well as the tolerability and safety are of particular interest.
Study Overview
Study Type
Observational
Enrollment (Actual)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Freiburg, Germany
- Swedish Orphan Biovitrum Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adult male and female patients with rheumatoid Arthritis who are treated with Kineret according to the therapeutic decision of the attending physician.
Description
Inclusion Criteria:
- Informed consent by the patient
- Rheumatoid arthritis
- Previous methotrexate therapy with inadequate response
Exclusion Criteria:
- Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease Activity Score 28 (DAS28)
Time Frame: 0-52 weeks
|
The DAS28 measures the progress and improvement of Rheumatoid Arthritis.
DAS28 values range from 2.0 to 10.0 while higher values mean a higher disease activity.
A DAS 28 below the value of 2.6 is interpreted as Remission.
Both the number of joints with tenderness upon touching and swelling are counted.
In addition, the erythrocyte sedimentation rate is measured.
Also, the patient makes a subjective assessment of disease activity during the preceding 7 days on a scale between 0 and 100, where 0 is "no activity" and 100 is "highest activity possible".
|
0-52 weeks
|
|
ACR response
Time Frame: 0-52 weeks
|
The ACR (American College of Rheumatology) Criteria measures the effectiveness of treatments for Rheumatoid Arthritis.
The ACR is reported as % improvement, comparing disease activity at two discrete time points.
|
0-52 weeks
|
|
Health Assessment Questionnaire
Time Frame: 0-52 weeks
|
The patients will at each visit complete a questionnaire about their health status and the impairment in usual activities due to the rheumatoid disorder.
|
0-52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Stefan Zeitler, MD, Swedish Orphan Biovitrum GmbH
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2012
Primary Completion (Actual)
January 1, 2016
Study Completion (Actual)
January 1, 2016
Study Registration Dates
First Submitted
September 23, 2016
First Submitted That Met QC Criteria
September 23, 2016
First Posted (Estimate)
September 26, 2016
Study Record Updates
Last Update Posted (Actual)
August 11, 2017
Last Update Submitted That Met QC Criteria
August 10, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KIRA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.